pd 98059 has been researched along with Cystic Fibrosis of Pancreas in 2 studies
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source
2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buchanan, PJ | 1 |
| McNally, P | 1 |
| Harvey, BJ | 1 |
| Urbach, V | 1 |
| Kerby, GS | 1 |
| Cottin, V | 1 |
| Accurso, FJ | 1 |
| Hoffmann, F | 1 |
| Chan, ED | 1 |
| Fadok, VA | 1 |
| Riches, DW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Comparative, Multicenter and Randomized Study Evaluating the Safety and Efficacy of RESPIMER® Netiflow® Versus Saline Solutions During Nasal Irrigation Following Bilateral Ethmoidectomy in the Treatment of Nasal Polyposis.[NCT02559284] | 189 participants (Actual) | Interventional | 2015-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for pd 98059 and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Lipoxin A₄-mediated KATP potassium channel activation results in cystic fibrosis airway epithelial repair.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cell Line, Transformed; Cell Proliferation; Cystic Fibrosis | 2013 |
Impairment of macrophage survival by NaCl: implications for early pulmonary inflammation in cystic fibrosis.
Topics: Animals; Apoptosis; Cell Survival; Cells, Cultured; Chromones; Cystic Fibrosis; Enzyme Inhibitors; F | 2002 |